MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...
The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback